TapewireFind a company

person · Reporting owner

Lim Bryant David

Disclosed activity across 2 companies

Tapewire entity
67554
SEC CIK
0001752888

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Aceragen, Inc.ACGN · Entity 110652SVP AND GENERAL COUNSELJanuary 20, 2023February 02, 2023
Prelude Therapeutics IncPRLD · Entity 5561CLO, CFO, Corp Sec.February 04, 2026February 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aceragen, Inc.

Report date January 20, 2023 · Filed February 02, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2033-01-20Direct25,400 Reported balance After 2023-01-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-01-20 · Grant · Acquired 25,400 · Balance 25,400

F1: The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

Prelude Therapeutics Inc

Report date February 04, 2026 · Filed February 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2036-02-03Direct275,000 Reported balance After 2026-02-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-02-04 · Grant · Acquired 275,000 · Balance 275,000

F1: The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 04, 2026 Filed Feb 5, 2026 21:11 UTC Prelude Therapeutics Inc PRLD · Entity 5561 GrantEmployee Stock Option (right to buy) · Derivative 275,000 $0.00 Strike: $2.30 $0.00
Disclosure

SEC source: 0001752888-26-000002 · primarydocument.xml · derivative · entry 1

Lim Bryant David · CIK 0001752888 · CLO, CFO, Corp Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires 2036-02-03

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
February 04, 2025 Filed Feb 5, 2025 21:34 UTC Prelude Therapeutics Inc PRLD · Entity 5561 GrantEmployee Stock Option (right to buy) · Derivative 200,000 $0.00 Strike: $1.11 $0.00
Disclosure

SEC source: 0001562180-25-000960 · primarydocument.xml · derivative · entry 1

Lim Bryant David · CIK 0001752888 · CLO, CFO, Corp Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2035-02-04

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on Feb 4, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
December 19, 2024 Filed Dec 20, 2024 12:35 UTC Prelude Therapeutics Inc PRLD · Entity 5561 PurchaseCommon Stock 25,000 $0.91 $22,637.50
Disclosure

SEC source: 0001562180-24-008532 · primarydocument.xml · nonDerivative · entry 1

Lim Bryant David · CIK 0001752888 · CLO, Interim CFO, Corp Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,400

F1 · price: 1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.87 to $0.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Read SEC document
May 14, 2024 Filed May 16, 2024 20:00 UTC Prelude Therapeutics Inc PRLD · Entity 5561 GrantEmployee Stock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $3.86 $0.00
Disclosure

SEC source: 0001562180-24-004084 · primarydocument.xml · derivative · entry 1

Lim Bryant David · CIK 0001752888 · CLO, Interim CFO, Corp Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-05-13

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on May 14, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
March 01, 2024 Filed Mar 4, 2024 23:07 UTC Prelude Therapeutics Inc PRLD · Entity 5561 GrantEmployee Stock Option (right to buy) · Derivative 150,000 $0.00 Strike: $4.59 $0.00
Disclosure

SEC source: 0001562180-24-002139 · primarydocument.xml · derivative · entry 1

Lim Bryant David · CIK 0001752888 · Chief Legal Officer, Corp Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2034-02-28

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on March 1, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
May 24, 2023 Filed May 25, 2023 20:07 UTC Prelude Therapeutics Inc PRLD · Entity 5561 PurchaseCommon Stock 2,400 $5.39 $12,936.00
Disclosure

SEC source: 0001562180-23-004479 · primarydocument.xml · nonDerivative · entry 1

Lim Bryant David · CIK 0001752888 · Chief Legal Officer, Corp Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,400

Read SEC document
March 01, 2023 Filed Mar 2, 2023 21:06 UTC Prelude Therapeutics Inc PRLD · Entity 5561 GrantEmployee Stock Option (Right to Buy) · Derivative 250,000 $0.00 Strike: $5.93 $0.00
Disclosure

SEC source: 0001562180-23-002144 · primarydocument.xml · derivative · entry 1

Lim Bryant David · CIK 0001752888 · Chief Legal Officer, Corp Sec.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2033-02-28

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on March 1, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
January 20, 2023 Filed Feb 2, 2023 20:08 UTC Aceragen, Inc. ACGN · Entity 110652 GrantStock Options (Right to Buy) · Derivative 25,400 $0.00 Strike: $5.21 $0.00
Disclosure

SEC source: 0001415889-23-001855 · form4-02032023_010247.xml · derivative · entry 1

Lim Bryant David · CIK 0001752888 · SVP AND GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,400

Underlying: Common Stock · 25,400 shares

Expires 2033-01-20

F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2022 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 20, 2023. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 20, 2024 (first anniversary of the date of grant) and the balance vests in thirty-six equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

Read SEC document
January 06, 2023 Filed Jan 10, 2023 21:17 UTC Aceragen, Inc. IDRA · Entity 110652 Tax withholdingCommon Stock 119,957 $0.71 $85,157.47
Disclosure

SEC source: 0001415889-23-000765 · form4-01112023_020118.xml · nonDerivative · entry 2

Lim Bryant David · CIK 0001752888 · SVP AND GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 309,695

F2 · shares: Represents the number of shares withheld by Issuer to cover tax obligations in connection with the grant of the shares of common stock.

Read SEC document
January 06, 2023 Filed Jan 10, 2023 21:17 UTC Aceragen, Inc. IDRA · Entity 110652 GrantCommon Stock 399,218 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-000765 · form4-01112023_020118.xml · nonDerivative · entry 1

Lim Bryant David · CIK 0001752888 · SVP AND GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 429,652

F1 · shares: Represents shares of common stock granted under the Idera Pharmaceuticals, Inc. 2013 Stock Incentive Plan, as amended and restated. The shares were granted pursuant to that certain Employment Continuation and Retention Bonus Letter Agreement, dated as of September 28, 2022, between the Issuer and Reporting Person.

Read SEC document
July 06, 2022 Filed Jul 7, 2022 17:33 UTC Aceragen, Inc. IDRA · Entity 110652 GrantStock Option (Right to Buy) · Derivative 66,500 $0.00 Strike: $0.43 $0.00
Disclosure

SEC source: 0001415889-22-007545 · form4-07072022_020709.xml · derivative · entry 1

Lim Bryant David · CIK 0001752888 · SVP AND GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,500

Underlying: Common Stock · 66,500 shares

Expires 2032-07-06

F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option will vest and become exercisable in full on July 6, 2026, with 25% vesting on July 6, 2023, and the remainder vesting in twelve equal quarterly installments over the remaining three years, subject to continued service with the Issuer.

Read SEC document
April 01, 2022 Filed Apr 4, 2022 17:44 UTC Aceragen, Inc. IDRA · Entity 110652 GrantStock Option (Right to Buy) · Derivative 41,500 $0.00 Strike: $0.54 $0.00
Disclosure

SEC source: 0001415889-22-003752 · form4-04042022_020430.xml · derivative · entry 1

Lim Bryant David · CIK 0001752888 · SVP AND GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,500

Underlying: Common Stock · 41,500 shares

Expires 2032-04-01

F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option will vest and become exercisable in full on January 24, 2026, with 25% vesting on January 24, 2023, and the remainder vesting in twelve equal quarterly installments over the remaining three years, subject to continued service with the Issuer.

Read SEC document
January 24, 2022 Filed Jan 26, 2022 20:43 UTC Aceragen, Inc. IDRA · Entity 110652 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $0.57 $0.00
Disclosure

SEC source: 0001415889-22-000793 · form4-01262022_050117.xml · derivative · entry 1

Lim Bryant David · CIK 0001752888 · SVP AND GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-01-24

F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 24, 2022. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 24, 2023 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

Read SEC document
July 08, 2021 Filed Jul 12, 2021 16:05 UTC Aceragen, Inc. IDRA · Entity 110652 GrantStock Option (Right to Buy) · Derivative 66,500 $0.00 Strike: $1.11 $0.00
Disclosure

SEC source: 0001415889-21-003585 · form4-07122021_040706.xml · derivative · entry 1

Lim Bryant David · CIK 0001752888 · SVP AND GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,500

Underlying: Common Stock · 66,500 shares

Expires 2031-07-08

F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on July 8, 2021. Twenty-five percent (25%) of the stock option vests and becomes exercisable on July 8, 2022 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

Read SEC document
March 25, 2021 Filed Mar 29, 2021 16:09 UTC Aceragen, Inc. IDRA · Entity 110652 SaleCommon Stock 7,630 $1.36 $10,377.56
Disclosure

SEC source: 0001415889-21-001672 · form4-03292021_010343.xml · nonDerivative · entry 1

Lim Bryant David · CIK 0001752888 · SVP AND GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,434

F1 · shares: Restricted Stock Units ("RSUs") granted to Reporting Person on January 3, 2019 and January 10, 2020 were accelerated and became fully vested on March 23, 2021. The amount reported in Column 4 represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 24,050 RSUs on March 23, 2021. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

Read SEC document
January 12, 2021 Filed Jan 12, 2021 19:08 UTC Aceragen, Inc. IDRA · Entity 110652 SaleCommon Stock 1,711 $4.21 $7,201.77
Disclosure

SEC source: 0001179110-21-000561 · edgar.xml · nonDerivative · entry 1

Lim Bryant David · CIK 0001752888 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,064

F1 · shares: Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 5,000 Restricted Stock Units ("RSUs") on January 10, 2021. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $4.1901 to $4.239 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Of the reported securities beneficially owned, 24,050 shares are represented by unvested RSUs.

Read SEC document
January 08, 2021 Filed Jan 12, 2021 19:08 UTC Aceragen, Inc. IDRA · Entity 110652 GrantStock Option (Right to Buy) · Derivative 51,000 $0.00 Strike: $4.28 $0.00
Disclosure

SEC source: 0001179110-21-000561 · edgar.xml · derivative · entry 2

Lim Bryant David · CIK 0001752888 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,000

Underlying: Common Stock · 51,000 shares

Expires 2031-01-08

F4 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 8, 2021. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 8, 2022 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

Read SEC document
January 05, 2021 Filed Jan 11, 2021 20:15 UTC Aceragen, Inc. IDRA · Entity 110652 SaleCommon Stock 1,465 $3.91 $5,722.00
Disclosure

SEC source: 0001179110-21-000525 · edgar.xml · nonDerivative · entry 1

Lim Bryant David · CIK 0001752888 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,775

F1 · shares: Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,525 Restricted Stock Units ("RSUs") on January 3, 2021. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $3.90 to $3.945 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Of the reported securities beneficially owned, 29,050 shares are represented by unvested RSUs.

Read SEC document
July 21, 2020 Filed Jul 23, 2020 16:37 UTC Aceragen, Inc. IDRA · Entity 110652 GrantStock Option (Right to Buy) · Derivative 50,000 $0.00 Strike: $2.48 $0.00
Disclosure

SEC source: 0001179110-20-008430 · edgar.xml · derivative · entry 1

Lim Bryant David · CIK 0001752888 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-07-21

F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on July 21, 2020. Twenty-five percent (25%) of the stock option vests and becomes exercisable on July 21, 2021 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

Read SEC document
January 10, 2020 Filed Jan 14, 2020 18:56 UTC Aceragen, Inc. IDRA · Entity 110652 GrantStock Option (Right to Buy) · Derivative 50,000 $0.00 Strike: $1.79 $0.00
Disclosure

SEC source: 0001179110-20-000565 · edgar.xml · derivative · entry 2

Lim Bryant David · CIK 0001752888 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-01-10

F3 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 10, 2020. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 10, 2021 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

Read SEC document
January 10, 2020 Filed Jan 14, 2020 18:56 UTC Aceragen, Inc. IDRA · Entity 110652 GrantCommon Stock 20,000 $0.00 $0.00
Disclosure

SEC source: 0001179110-20-000565 · edgar.xml · nonDerivative · entry 1

Lim Bryant David · CIK 0001752888 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,240

F1 · shares: Represents a restricted stock unit ("RSU") award granted under the Issuer's 2013 Stock Incentive Plan. Each RSU represents a right to receive one share of Issuer common stock. The RSU award vests over a four-year period commencing on January 10, 2020. Twenty-five percent (25%) of the shares subject to the RSU award shall vest on each one-year anniversary of the grant date of the award.

F2 · balance_after: Securities beneficially owned totaling 41,240 includes 7,665 shares of Issuer common stock owned and 33,575 of unvested RSU's held by the reporting person.

Read SEC document
January 07, 2020 Filed Jan 10, 2020 08:07 UTC Aceragen, Inc. IDRA · Entity 110652 SaleCommon Stock 1,603 $1.78 $2,853.98
Disclosure

SEC source: 0001179110-20-000446 · edgar.xml · nonDerivative · entry 1

Lim Bryant David · CIK 0001752888 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,240

F1 · shares: Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,525 Restricted Stock Units ("RSUs") on January 3, 2020. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.76 to $1.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Of the reported shares, 13,575 shares are represented by unvested RSUs.

Read SEC document
January 07, 2020 Filed Jan 14, 2020 18:10 UTC Amendment Aceragen, Inc. IDRA · Entity 110652 SaleCommon Stock 1,603 $1.78 $2,853.98
Disclosure

SEC source: 0001179110-20-000560 · edgar.xml · nonDerivative · entry 1

Lim Bryant David · CIK 0001752888 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,240

F1 · deemedExecutionDate: The Form 4 filed on January 10, 2020 did not include the Deemed Execution Date in Column 2A and corresponding footnote disclosure. This amendment to the Form 4 is being filed to include this information for the reported transaction.

F2 · deemedExecutionDate: In accordance with terms of the RSU agreement, the "sell to cover" provision is intended to comply with the requirements of Rule 10b5-1(c)(1) under the Exchange Act and be interpreted to comply with the requirements of Rule 10b5-1(c) under the Exchange Act.

F3 · shares: Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,525 Restricted Stock Units ("RSUs") on January 3, 2020. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F4 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.76 to $1.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5 · balance_after: Of the reported shares, 13,575 shares are represented by unvested RSUs.

Read SEC document
July 09, 2019 Filed Jul 11, 2019 17:17 UTC Aceragen, Inc. IDRA · Entity 110652 GrantStock Option (Right to Buy) · Derivative 45,500 $0.00 Strike: $2.52 $0.00
Disclosure

SEC source: 0001179110-19-008594 · edgar.xml · derivative · entry 1

Lim Bryant David · CIK 0001752888 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,500

Underlying: Common Stock · 45,500 shares

Expires 2029-07-09

F1 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on July 9, 2019. Twenty-five percent (25%) of the stock option vests and becomes exercisable on July 9, 2020 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

Read SEC document
January 03, 2019 Filed Jan 7, 2019 20:14 UTC Aceragen, Inc. IDRA · Entity 110652 GrantStock Option (Right to Buy) · Derivative 45,500 $0.00 Strike: $3.14 $0.00
Disclosure

SEC source: 0001179110-19-000528 · edgar.xml · derivative · entry 2

Lim Bryant David · CIK 0001752888 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,500

Underlying: Common Stock · 45,500 shares

Expires 2029-01-03

F3 · derivative.exercise_date: The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 3, 2019. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 3, 2020 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

Read SEC document
January 03, 2019 Filed Jan 7, 2019 20:14 UTC Aceragen, Inc. IDRA · Entity 110652 GrantCommon Stock 18,100 $0.00 $0.00
Disclosure

SEC source: 0001179110-19-000528 · edgar.xml · nonDerivative · entry 1

Lim Bryant David · CIK 0001752888 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,843

F1 · shares: Represents a restricted stock unit ("RSU") award granted under the Issuer's 2013 Stock Incentive Plan. Each RSU represents a right to receive one share of Issuer common stock. The RSU award vests over a four-year period commencing on January 3, 2019. Twenty-five percent (25%) of the shares subject to the RSU award shall vest on each one-year anniversary of the grant date of the award.

F2 · balance_after: Securities beneficially owned totaling 22,843 includes 4,743 shares of Issuer common stock owned and 18,100 of unvested RSU's held by the reporting person.

Read SEC document
December 21, 2018 Filed Dec 26, 2018 09:17 UTC Aceragen, Inc. IDRA · Entity 110652 PurchaseCommon Stock 4,000 $3.05 $12,200.00
Disclosure

SEC source: 0001179110-18-014243 · edgar.xml · nonDerivative · entry 1

Lim Bryant David · CIK 0001752888 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,743

Read SEC document
September 10, 2018 Filed Sep 13, 2018 16:20 UTC Aceragen, Inc. IDRA · Entity 110652 GrantStock Option (Right to Buy) · Derivative 130,000 $0.00 Strike: $9.29 $0.00
Disclosure

SEC source: 0001179110-18-011368 · edgar.xml · derivative · entry 1

Lim Bryant David · CIK 0001752888 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2028-09-10

F1 · derivative.exercise_date: The option was granted under the Company's 2013 Stock Incentive Plan. The option vests and becomes exercisable over a four-year period commencing on September 10, 2018. Twenty-five percent (25%) of the option vests and becomes exercisable on September 10, 2019 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.